PolyPid (PYPD) EPS (Basic) (2019 - 2026)

PolyPid (PYPD) posted EPS (Basic) of $0.35 for Q1 2026, down 31.97% sequentially from $0.52 in Q4 2025, and down 49.9% YoY from $0.7 in Q1 2025.

PolyPid (PYPD) EPS (Basic) (2019 - 2026) Analysis & Trends

PolyPid has reported EPS (Basic) for 8 years, with the latest figure at $0.35 in Q1 2026.

Quarterly EPS (Basic) fell 49.9% year-over-year to $0.35 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.53 (down 26.78% YoY) and the FY2025 annual result came in at $0.52, down 64.04% from the prior year.
EPS (Basic) fell to $0.35 in Q1 2026 per PYPD's latest filing, from $0.52 in the prior quarter.
Over five years, EPS (Basic) peaked at $18.81 in Q1 2022 and troughed at $0.0 in Q2 2024.
A 5-year average of $3.88 and a median of $1.21 in 2024 frame the typical range for EPS (Basic).
The sharpest annual moves came in 2022 and 2025: EPS (Basic) plunged 100.0% in 2022, then jumped 308998283.56% in 2025.
Over 5 years, EPS (Basic) stood at $10.09 in 2022, then tumbled by 55.28% to $4.51 in 2023, then plunged by 68.07% to $1.44 in 2024, then plunged by 64.04% to $0.52 in 2025, then slumped by 31.97% to $0.35 in 2026.
According to Business Quant data, EPS (Basic) over the past three periods registered $0.35, $0.52, and $0.37 for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EPS (Basic) (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	4.34
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	12.62
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	7.59
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-1.96
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	2.12
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	1.23
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	-0.06
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	0.18
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	-0.72
10	PolyPid	113.30 Mn	106.53 Mn	-	0.35

Download Data